WHEN Krishna Ella went to venture capitalists in 1995 he was laughed out of their offices. A molecular biologist at the University of Wisconsin in Madison, he was proposing to make hepatitis B vaccine in India, his native land, for a mere dollar a shot.
Office of Strategic Communication